US 11,951,190 B2
Use of labeled inhibitors of prostate specific membrane antigen (PSMA), as agents for the treatment of prostate cancer
Matthias Eder, Mannheim (DE); Klaus Kopka, Dossenheim (DE); Martin Schäfer, Neckarsteinach (DE); Ulrike Bauder-Wüst, Schriesheim (DE); Michael Eisenhut, Heidelberg (DE); Walter Mier, Bensheim (DE); and Martina Benesova, Heidelberg (DE)
Assigned to NOVARTIS AG, Basel (CH)
Filed by DEUTSCHES KREBSFORSCHUNGSZENTRUM, Heidelberg (DE); and RUPRECHT-KARLS-UNIVERSITÄT HEIDELBERG, Heidelberg (DE)
Filed on Jan. 7, 2021, as Appl. No. 17/143,280.
Application 17/143,280 is a continuation of application No. 16/510,495, filed on Jul. 12, 2019, abandoned.
Application 16/510,495 is a continuation of application No. 16/114,988, filed on Aug. 28, 2018, granted, now 10,398,791, issued on Sep. 3, 2019.
Application 16/114,988 is a continuation of application No. 15/131,118, filed on Apr. 18, 2016, abandoned.
Application 15/131,118 is a continuation in part of application No. PCT/EP2014/002808, filed on Oct. 17, 2014.
Claims priority of application No. 13004991 (EP), filed on Oct. 18, 2013; and application No. 14175612 (EP), filed on Jul. 3, 2014.
Prior Publication US 2021/0283279 A1, Sep. 16, 2021
Int. Cl. A61K 51/04 (2006.01); C07B 59/00 (2006.01); C07D 257/02 (2006.01); C07D 295/145 (2006.01)
CPC A61K 51/0482 (2013.01) [A61K 51/0402 (2013.01); A61K 51/0497 (2013.01); C07B 59/002 (2013.01); C07D 257/02 (2013.01); C07D 295/145 (2013.01)] 62 Claims
 
1. A method of treating prostate cancer and/or a metastasis thereof, comprising administering to a patient a therapeutically effective amount of a compound of the formula:

OG Complex Work Unit Chemistry
and/or a salt thereof,
wherein R′ is a chelator of the formula:

OG Complex Work Unit Chemistry
wherein a radionuclide is complexed to the chelator.